Placeholder Banner

BIO Statement on California Governor Brown Signing Drug Price Reporting & Transparency Bill

October 9, 2017

Washington, D.C. (October 9, 2017) – Biotechnology Innovation Organization (BIO) Senior Executive Vice President for Public Affairs Gary Andres issued the following statement following California Governor Jerry Brown’s signing of the drug price reporting and transparency bill Senate Bill 17 into law:

“As the world’s leader in biopharmaceutical innovation, California is home to over 2,800 companies that employ a workforce of over 242,000 dedicated men and women focused on innovative solutions to improving human health and increased patient access to breakthrough medicines.

“The legislation the Governor signed into law seriously jeopardizes the future of California’s leadership in this innovative industry. Despite its intent, this law will neither provide meaningful information to patients nor lower prescription drug costs.

“By ignoring the realities of biopharmaceutical development, Senate Bill 17 will delay or prevent future biopharmaceutical innovation by driving investment toward other industry sectors that are not burdened with this type of misguided government intrusion.”

###

Discover More
Washington, D.C. (January 20, 2021) — The BiotechnologyInnovation Organization (BIO) and the Low Carbon Fuels Coalition (LCFC) today released the following statement in support of New Mexico Governor Michelle Lujan Grisham’s inclusion of a…
In his last day in office, former President Donald Trump proposed a sweeping change to Medicare’s “Part D” drug benefit. Billed as a demonstration project through the Centers for Medicare and Medicaid Innovation (CMMI), this new policy would allow…
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO) made the following remarks after President Joe Biden and Vice President Kamala Harris were sworn into office:  “On behalf of the Biotechnology…